+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Endometrial Cancer Treatment Market - Global Forecast 2026-2032- Product Image
Endometrial Cancer Treatment Market - Global Forecast 2026-2032- Product Image
New

Endometrial Cancer Treatment Market - Global Forecast 2026-2032

  • PDF Icon

    Report

  • 199 Pages
  • January 2026
  • Region: Global
  • 360iResearch™
  • ID: 5888365
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The endometrial cancer treatment market is undergoing significant transformation as advances in diagnostics, targeted therapeutics, and care delivery models reshape how care is delivered and accessed. Senior decision-makers face complex challenges and opportunities in navigating emerging standards, managing costs, and supporting patient outcomes.

Market Snapshot: Endometrial Cancer Treatment Market Growth

In 2025, the endometrial cancer treatment market was valued at USD 9.38 billion and is projected to rise to USD 9.93 billion in 2026. A compound annual growth rate of 7.69% will drive the market to USD 15.77 billion by 2032, reflecting steady expansion. Sustained momentum stems from the adoption of molecular stratification techniques, growth in combination therapies, and evolving regulatory frameworks that inform commercialization and approval pathways. This expansion is further influenced by advances in clinical practice, increasing demand for precision medicine, and integration of novel technologies across care environments.

Scope & Segmentation

This comprehensive analysis maps the dimensions shaping growth and strategic action in the endometrial cancer treatment market:

  • Therapeutic Modalities: Covers surgery, radiation therapy, chemotherapy, targeted therapy, immunotherapy, hormone therapy, and combined interventions within the treatment continuum.
  • Drug Mechanisms: Addresses antiangiogenic agents, platinum-based and taxane chemotherapies, hormonal agents such as aromatase inhibitors and progestins, as well as immunotherapies targeting CTLA-4 and PD-1, alongside targeted agents including mTOR, PARP, and tyrosine kinase inhibitors.
  • Lines of Therapy: Includes first through fourth-line approaches and subsequent lines, with shifting positioning determined by emerging clinical evidence and endpoint requirements.
  • Administration Routes: Examines intravenous and oral options, noting the impact on patient adherence, decentralized care models, and associated cost structures.
  • Care Settings: Reviews ambulatory, hospital outpatient, and hospital inpatient environments, exploring implications for access, reimbursement, and adoption.
  • Regions: Considers market dynamics across the Americas, Europe, Middle East & Africa, and Asia-Pacific, detailing how regional factors, access barriers, and procurement strategies influence adoption and market entry.
  • Technologies: Highlights molecular diagnostics, biomarker-guided treatment decisions, immune checkpoint inhibitors, and the role of next-generation targeted therapeutics in clinical adoption and commercial success.

Integrated Diagnostic and Therapeutic Innovations

Innovation in molecular profiling is transforming care pathways, allowing clinicians to match therapies to tumor biology with greater precision. New approaches in therapeutic delivery are converging with progress in diagnostics, supporting more personalized care. Regulatory developments and payer requirements are also prompting industry stakeholders to adapt clinical development strategies, integrate health economics into trial design, and align commercialization practices with evolving value-based care expectations.

Key Takeaways for Decision-Makers

  • Molecular stratification is enabling more refined patient targeting, resulting in improved therapy selection and outcomes.
  • Immune-oncology, in combination with targeted therapies and immune checkpoint inhibitors, is driving change in clinical practice and shaping new standards of care.
  • Oral agents and decentralized care models are transforming traditional cost structures, enhancing patient convenience, and influencing procurement and reimbursement strategies.
  • Regulatory demands are increasing the requirement for evidence not only of clinical efficacy but also of economic value, elevating the importance of integrated health economics and outcomes research in market access.
  • Industry collaboration—among manufacturers, diagnostic providers, and supply chain partners—is becoming essential for achieving market access and maintaining continuity across diverse regional markets.

Tariff Impact on Supply, Procurement, and Pricing

Recent changes to tariffs in 2025 have introduced new cost drivers across the endometrial cancer treatment landscape. Adjusted duties have affected costs for active pharmaceutical ingredients, diagnostic reagents, and finished medical devices, disrupting established procurement and pricing structures. In response, manufacturers and health systems are increasing inventory buffers, diversifying supply sources, and negotiating revised logistics contracts. For diagnostics, higher tariffs are challenging adoption by raising costs, making it vital for stakeholders to adopt targeted access and pricing solutions that ensure sustained utilization across global markets.

Methodology & Data Sources

This report integrates evidence from peer-reviewed literature, clinical trial registries, regulatory documents, and focused expert interviews. Input from gynecologic oncologists, diagnostic pathologists, payer analysts, and supply chain professionals enriches the analysis, which includes clinical performance, payer perspectives, and supply chain modeling, supported by real-world evidence when available.

Why This Report Matters

  • Offers actionable segmentation by therapy, mechanism, line of use, and care environment, identifying high-value opportunities for commercialization and growth.
  • Equips decision-makers with in-depth supply chain, procurement, and payer landscape intelligence to support strategic planning and market access initiatives.
  • Delivers scenario-based recommendations that address tariff challenges, helping ensure clinical continuity across regions.

Conclusion

Sustained progress in endometrial cancer treatment will rely on integrating genomic insights, combination therapies, and robust supply chain strategies. Stakeholders prepared to align commercial, clinical, and operational priorities will best position themselves for continued access and success in an evolving market landscape.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Porter’s Five Forces Analysis
4.4. PESTLE Analysis
4.5. Market Outlook
4.5.1. Near-Term Market Outlook (0-2 Years)
4.5.2. Medium-Term Market Outlook (3-5 Years)
4.5.3. Long-Term Market Outlook (5-10 Years)
4.6. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of United States Tariffs 2025
7. Cumulative Impact of Artificial Intelligence 2025
8. Endometrial Cancer Treatment Market, by Treatment Type
8.1. Chemotherapy
8.2. Combination Therapy
8.3. Hormone Therapy
8.4. Immunotherapy
8.5. Radiation Therapy
8.6. Surgery
8.7. Targeted Therapy
9. Endometrial Cancer Treatment Market, by Drug Class
9.1. Antiangiogenic Therapy
9.2. Chemotherapeutic Agents
9.2.1. Platinum Based Agents
9.2.2. Taxanes
9.3. Hormonal Therapy
9.3.1. Aromatase Inhibitors
9.3.2. Progestins
9.4. Immunotherapy
9.4.1. CTLA-4 Inhibitors
9.4.2. PD-1 Inhibitors
9.5. Targeted Therapy
9.5.1. MTOR Inhibitors
9.5.2. PARP Inhibitors
9.5.3. Tyrosine Kinase Inhibitors
10. Endometrial Cancer Treatment Market, by Line Of Therapy
10.1. First Line
10.2. Fourth Line And Beyond
10.3. Second Line
10.4. Third Line
11. Endometrial Cancer Treatment Market, by Administration Setting
11.1. Ambulatory Care
11.2. Hospital Inpatient
11.3. Hospital Outpatient
12. Endometrial Cancer Treatment Market, by Mode Of Administration
12.1. Intravenous
12.2. Oral
13. Endometrial Cancer Treatment Market, by Region
13.1. Americas
13.1.1. North America
13.1.2. Latin America
13.2. Europe, Middle East & Africa
13.2.1. Europe
13.2.2. Middle East
13.2.3. Africa
13.3. Asia-Pacific
14. Endometrial Cancer Treatment Market, by Group
14.1. ASEAN
14.2. GCC
14.3. European Union
14.4. BRICS
14.5. G7
14.6. NATO
15. Endometrial Cancer Treatment Market, by Country
15.1. United States
15.2. Canada
15.3. Mexico
15.4. Brazil
15.5. United Kingdom
15.6. Germany
15.7. France
15.8. Russia
15.9. Italy
15.10. Spain
15.11. China
15.12. India
15.13. Japan
15.14. Australia
15.15. South Korea
16. United States Endometrial Cancer Treatment Market
17. China Endometrial Cancer Treatment Market
18. Competitive Landscape
18.1. Market Concentration Analysis, 2025
18.1.1. Concentration Ratio (CR)
18.1.2. Herfindahl Hirschman Index (HHI)
18.2. Recent Developments & Impact Analysis, 2025
18.3. Product Portfolio Analysis, 2025
18.4. Benchmarking Analysis, 2025
18.5. Abbott Laboratories
18.6. AstraZeneca PLC
18.7. Bayer AG
18.8. Becton, Dickinson and Company
18.9. Boston Scientific Corporation
18.10. Bristol-Myers Squibb Company
18.11. Celgene Corporation
18.12. Context Therapeutics Inc.
18.13. CooperSurgical Inc.
18.14. Eisai Co., Ltd.
18.15. Elekta AB
18.16. F. Hoffmann-La Roche AG
18.17. General Electric Company
18.18. GlaxoSmithKline PLC
18.19. Hologic Inc.
18.20. Johnson & Johnson Services, Inc.
18.21. Karyopharm Therapeutics Inc.
18.22. Koninklijke Philips N.V.
18.23. LiNA Medical ApS
18.24. Merck & Co., Inc.
18.25. Novartis AG
18.26. Pfizer Inc.
18.27. Sanofi S.A.
18.28. Siemens Healthineers AG
18.29. Takeda Pharmaceutical Company Limited
List of Figures
FIGURE 1. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 2. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 3. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET, FPNV POSITIONING MATRIX, 2025
FIGURE 4. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 5. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 6. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 7. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY ADMINISTRATION SETTING, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 9. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 11. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. UNITED STATES ENDOMETRIAL CANCER TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 13. CHINA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
List of Tables
TABLE 1. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 2. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 7. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY COMBINATION THERAPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 8. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY COMBINATION THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HORMONE THERAPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HORMONE THERAPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HORMONE THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY RADIATION THERAPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY RADIATION THERAPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY RADIATION THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY SURGERY, BY REGION, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY SURGERY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY SURGERY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY ANTIANGIOGENIC THERAPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY ANTIANGIOGENIC THERAPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY ANTIANGIOGENIC THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPEUTIC AGENTS, BY REGION, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPEUTIC AGENTS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPEUTIC AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPEUTIC AGENTS, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY PLATINUM BASED AGENTS, BY REGION, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY PLATINUM BASED AGENTS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY PLATINUM BASED AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TAXANES, BY REGION, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TAXANES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TAXANES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HORMONAL THERAPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HORMONAL THERAPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HORMONAL THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HORMONAL THERAPY, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY AROMATASE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY AROMATASE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY AROMATASE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY PROGESTINS, BY REGION, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY PROGESTINS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY PROGESTINS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY CTLA-4 INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY CTLA-4 INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY CTLA-4 INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY PD-1 INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY PD-1 INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY PD-1 INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY MTOR INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY MTOR INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY MTOR INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 65. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY PARP INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 66. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY PARP INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 67. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY PARP INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 68. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 69. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 70. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 71. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 72. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2032 (USD MILLION)
TABLE 73. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY FIRST LINE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 74. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY FIRST LINE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 75. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY FOURTH LINE AND BEYOND, BY REGION, 2018-2032 (USD MILLION)
TABLE 76. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY FOURTH LINE AND BEYOND, BY GROUP, 2018-2032 (USD MILLION)
TABLE 77. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY FOURTH LINE AND BEYOND, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 78. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2032 (USD MILLION)
TABLE 79. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY SECOND LINE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 80. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY SECOND LINE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 81. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY THIRD LINE, BY REGION, 2018-2032 (USD MILLION)
TABLE 82. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY THIRD LINE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 83. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY THIRD LINE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 84. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY ADMINISTRATION SETTING, 2018-2032 (USD MILLION)
TABLE 85. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY AMBULATORY CARE, BY REGION, 2018-2032 (USD MILLION)
TABLE 86. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY AMBULATORY CARE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 87. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY AMBULATORY CARE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 88. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HOSPITAL INPATIENT, BY REGION, 2018-2032 (USD MILLION)
TABLE 89. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HOSPITAL INPATIENT, BY GROUP, 2018-2032 (USD MILLION)
TABLE 90. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HOSPITAL INPATIENT, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 91. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HOSPITAL OUTPATIENT, BY REGION, 2018-2032 (USD MILLION)
TABLE 92. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HOSPITAL OUTPATIENT, BY GROUP, 2018-2032 (USD MILLION)
TABLE 93. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HOSPITAL OUTPATIENT, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 94. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 95. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
TABLE 96. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 97. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 98. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 99. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 100. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 101. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 102. AMERICAS ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 103. AMERICAS ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 104. AMERICAS ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 105. AMERICAS ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPEUTIC AGENTS, 2018-2032 (USD MILLION)
TABLE 106. AMERICAS ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HORMONAL THERAPY, 2018-2032 (USD MILLION)
TABLE 107. AMERICAS ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 108. AMERICAS ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 109. AMERICAS ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 110. AMERICAS ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY ADMINISTRATION SETTING, 2018-2032 (USD MILLION)
TABLE 111. AMERICAS ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 112. NORTH AMERICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 113. NORTH AMERICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 114. NORTH AMERICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 115. NORTH AMERICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPEUTIC AGENTS, 2018-2032 (USD MILLION)
TABLE 116. NORTH AMERICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HORMONAL THERAPY, 2018-2032 (USD MILLION)
TABLE 117. NORTH AMERICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 118. NORTH AMERICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 119. NORTH AMERICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 120. NORTH AMERICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY ADMINISTRATION SETTING, 2018-2032 (USD MILLION)
TABLE 121. NORTH AMERICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 122. LATIN AMERICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 123. LATIN AMERICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 124. LATIN AMERICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 125. LATIN AMERICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPEUTIC AGENTS, 2018-2032 (USD MILLION)
TABLE 126. LATIN AMERICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HORMONAL THERAPY, 2018-2032 (USD MILLION)
TABLE 127. LATIN AMERICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 128. LATIN AMERICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 129. LATIN AMERICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 130. LATIN AMERICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY ADMINISTRATION SETTING, 2018-2032 (USD MILLION)
TABLE 131. LATIN AMERICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 132. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 133. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 134. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 135. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPEUTIC AGENTS, 2018-2032 (USD MILLION)
TABLE 136. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HORMONAL THERAPY, 2018-2032 (USD MILLION)
TABLE 137. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 138. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 139. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 140. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY ADMINISTRATION SETTING, 2018-2032 (USD MILLION)
TABLE 141. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 142. EUROPE ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 143. EUROPE ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 144. EUROPE ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 145. EUROPE ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPEUTIC AGENTS, 2018-2032 (USD MILLION)
TABLE 146. EUROPE ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HORMONAL THERAPY, 2018-2032 (USD MILLION)
TABLE 147. EUROPE ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 148. EUROPE ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 149. EUROPE ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 150. EUROPE ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY ADMINISTRATION SETTING, 2018-2032 (USD MILLION)
TABLE 151. EUROPE ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 152. MIDDLE EAST ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 153. MIDDLE EAST ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 154. MIDDLE EAST ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 155. MIDDLE EAST ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPEUTIC AGENTS, 2018-2032 (USD MILLION)
TABLE 156. MIDDLE EAST ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HORMONAL THERAPY, 2018-2032 (USD MILLION)
TABLE 157. MIDDLE EAST ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 158. MIDDLE EAST ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 159. MIDDLE EAST ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 160. MIDDLE EAST ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY ADMINISTRATION SETTING, 2018-2032 (USD MILLION)
TABLE 161. MIDDLE EAST ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 162. AFRICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 163. AFRICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 164. AFRICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 165. AFRICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPEUTIC AGENTS, 2018-2032 (USD MILLION)
TABLE 166. AFRICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HORMONAL THERAPY, 2018-2032 (USD MILLION)
TABLE 167. AFRICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 168. AFRICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 169. AFRICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 170. AFRICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY ADMINISTRATION SETTING, 2018-2032 (USD MILLION)
TABLE 171. AFRICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 172. ASIA-PACIFIC ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 173. ASIA-PACIFIC ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 174. ASIA-PACIFIC ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 175. ASIA-PACIFIC ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPEUTIC AGENTS, 2018-2032 (USD MILLION)
TABLE 176. ASIA-PACIFIC ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HORMONAL THERAPY, 2018-2032 (USD MILLION)
TABLE 177. ASIA-PACIFIC ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 178. ASIA-PACIFIC ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 179. ASIA-PACIFIC ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 180. ASIA-PACIFIC ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY ADMINISTRATION SETTING, 2018-2032 (USD MILLION)
TABLE 181. ASIA-PACIFIC ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 182. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 183. ASEAN ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 184. ASEAN ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 185. ASEAN ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 186. ASEAN ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPEUTIC AGENTS, 2018-2032 (USD MILLION)
TABLE 187. ASEAN ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HORMONAL THERAPY, 2018-2032 (USD MILLION)
TABLE 188. ASEAN ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 189. ASEAN ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 190. ASEAN ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 191. ASEAN ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY ADMINISTRATION SETTING, 2018-2032 (USD MILLION)
TABLE 192. ASEAN ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 193. GCC ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 194. GCC ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 195. GCC ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 196. GCC ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPEUTIC AGENTS, 2018-2032 (USD MILLION)
TABLE 197. GCC ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HORMONAL THERAPY, 2018-2032 (USD MILLION)
TABLE 198. GCC ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 199. GCC ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 200. GCC ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 201. GCC ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY ADMINISTRATION SETTING, 2018-2032 (USD MILLION)
TABLE 202. GCC ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 203. EUROPEAN UNION ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 204. EUROPEAN UNION ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 205. EUROPEAN UNION ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 206. EUROPEAN UNION ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPEUTIC AGENTS, 2018-2032 (USD MILLION)
TABLE 207. EUROPEAN UNION ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HORMONAL THERAPY, 2018-2032 (USD MILLION)
TABLE 208. EUROPEAN UNION ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 209. EUROPEAN UNION ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 210. EUROPEAN UNION ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 211. EUROPEAN UNION ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY ADMINISTRATION SETTING, 2018-2032 (USD MILLION)
TABLE 212. EUROPEAN UNION ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 213. BRICS ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 214. BRICS ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 215. BRICS ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 216. BRICS ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPEUTIC AGENTS, 2018-2032 (USD MILLION)
TABLE 217. BRICS ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HORMONAL THERAPY, 2018-2032 (USD MILLION)
TABLE 218. BRICS ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 219. BRICS ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 220. BRICS ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 221. BRICS ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY ADMINISTRATION SETTING, 2018-2032 (USD MILLION)
TABLE 222. BRICS ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 223. G7 ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 224. G7 ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 225. G7 ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 226. G7 ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPEUTIC AGENTS, 2018-2032 (USD MILLION)
TABLE 227. G7 ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HORMONAL THERAPY, 2018-2032 (USD MILLION)
TABLE 228. G7 ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 229. G7 ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 230. G7 ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 231. G7 ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY ADMINISTRATION SETTING, 2018-2032 (USD MILLION)
TABLE 232. G7 ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 233. NATO ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 234. NATO ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 235. NATO ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 236. NATO ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPEUTIC AGENTS, 2018-2032 (USD MILLION)
TABLE 237. NATO ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HORMONAL THERAPY, 2018-2032 (USD MILLION)
TABLE 238. NATO ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 239. NATO ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 240. NATO ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 241. NATO ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY ADMINISTRATION SETTING, 2018-2032 (USD MILLION)
TABLE 242. NATO ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 243. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 244. UNITED STATES ENDOMETRIAL CANCER TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 245. UNITED STATES ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 246. UNITED STATES ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 247. UNITED STATES ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPEUTIC AGENTS, 2018-2032 (USD MILLION)
TABLE 248. UNITED STATES ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HORMONAL THERAPY, 2018-2032 (USD MILLION)
TABLE 249. UNITED STATES ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 250. UNITED STATES ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 251. UNITED STATES ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 252. UNITED STATES ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY ADMINISTRATION SETTING, 2018-2032 (USD MILLION)
TABLE 253. UNITED STATES ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 254. CHINA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 255. CHINA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 256. CHINA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 257. CHINA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPEUTIC AGENTS, 2018-2032 (USD MILLION)
TABLE 258. CHINA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HORMONAL THERAPY, 2018-2032 (USD MILLION)
TABLE 259. CHINA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 260. CHINA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 261. CHINA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 262. CHINA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY ADMINISTRATION SETTING, 2018-2032 (USD MILLION)
TABLE 263. CHINA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)

Companies Mentioned

The key companies profiled in this Endometrial Cancer Treatment market report include:
  • Abbott Laboratories
  • AstraZeneca PLC
  • Bayer AG
  • Becton, Dickinson and Company
  • Boston Scientific Corporation
  • Bristol-Myers Squibb Company
  • Celgene Corporation
  • Context Therapeutics Inc.
  • CooperSurgical Inc.
  • Eisai Co., Ltd.
  • Elekta AB
  • F. Hoffmann-La Roche AG
  • General Electric Company
  • GlaxoSmithKline PLC
  • Hologic Inc.
  • Johnson & Johnson Services, Inc.
  • Karyopharm Therapeutics Inc.
  • Koninklijke Philips N.V.
  • LiNA Medical ApS
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi S.A.
  • Siemens Healthineers AG
  • Takeda Pharmaceutical Company Limited

Table Information

Report AttributeDetails
No. of Pages199
PublishedJanuary 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 9.93 Billion
Forecasted Market Value ( USD ) by 2032 $ 15.77 Billion
Compound Annual Growth Rate7.6%
Regions CoveredGlobal
No. of Companies Mentioned26

Related Topics

Related Reports

Endometrial Cancer Treatment Market Outlook 2025-2034: Market Share, and Growth Analysis - Product Image

Endometrial Cancer Treatment Market Outlook 2025-2034: Market Share, and Growth Analysis

  • Report
  • 160 Pages
  • Global
From
Endometrial Cancer Treatment Market Report 2025 - Product Image

Endometrial Cancer Treatment Market Report 2025

  • Report
  • 250 Pages
  • Global
From
Endometrial Cancer Treatment - Global Strategic Business Report - Product Image

Endometrial Cancer Treatment - Global Strategic Business Report

  • Report
  • 192 Pages
  • Global
From
Endometrial Cancer Market Report: Trends, Forecast and Competitive Analysis to 2031 - Product Image

Endometrial Cancer Market Report: Trends, Forecast and Competitive Analysis to 2031

  • Report
  • 150 Pages
  • Global
From
Endometrial Cancer Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031 - Product Image

Endometrial Cancer Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031

  • Report
  • 185 Pages
  • Global
From

About the Endometrial Cancer Drug Market

The Endometrial Cancer Drug market is a subset of the Uterine Cancer Drugs market, which is composed of drugs used to treat endometrial cancer, a type of cancer that affects the lining of the uterus. Endometrial cancer drugs are typically used to reduce the size of tumors, reduce the spread of cancer cells, and reduce the risk of recurrence. Commonly used drugs include hormone therapy, chemotherapy, targeted therapy, and immunotherapy. Hormone therapy is used to reduce the amount of estrogen in the body, while chemotherapy is used to kill cancer cells. Targeted therapy is used to target specific cancer cells, while immunotherapy is used to boost the body's immune system to fight cancer. Some companies in the Endometrial Cancer Drug market include AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Merck, and Pfizer. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.